NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $9.10 +0.71 (+8.46%) (As of 03:59 PM ET) Add Compare Share Share Today's Range$8.27▼$9.2050-Day Range$7.35▼$9.7352-Week Range$4.52▼$11.56Volume1.29 million shsAverage Volume2.38 million shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$10.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Maravai LifeSciences alerts: Email Address Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside18.7% Upside$10.78 Price TargetShort InterestHealthy3.33% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment1.05Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.17) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector60th out of 927 stocksBiotechnology Industry1st out of 18 stocks 3.3 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMaravai LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maravai LifeSciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.33% of the outstanding shares of Maravai LifeSciences have been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently decreased by 0.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 3.4 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search Interest6 people have searched for MRVI on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.63% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.17) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesSeptember 10, 2024 | markets.businessinsider.comMaravai Lifesciences Holdings (MRVI) Gets a Buy from Wells FargoSeptember 8, 2024 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Moderate Buy" by AnalystsSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.August 29, 2024 | msn.comWells Fargo Initiates Coverage of Maravai LifeSciences Holdings (MRVI) with Overweight RecommendationAugust 20, 2024 | nasdaq.comMRVI Quantitative Stock AnalysisAugust 18, 2024 | finance.yahoo.comCURE Sep 2024 124.000 call (CURE240920C00124000)August 16, 2024 | msn.comMaravai LifeSciences jumps on report of Repligen takeover offerAugust 16, 2024 | msn.comMaravai LifeSciences may be worth $15 to $20 share in a takeout - analystSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.August 14, 2024 | msn.comMorgan Stanley Downgrades Maravai LifeSciences Holdings (MRVI)August 13, 2024 | markets.businessinsider.comMaravai Lifesciences: Hold Rating Amidst Mixed Performance and Revised EBITDA Margin GuidanceAugust 13, 2024 | msn.comMaravai cut at Morgan Stanley; Pfizer/BioNTech headwinds citedAugust 12, 2024 | globenewswire.comMaravai LifeSciences Announces August and September 2024 Investor Conference ScheduleAugust 9, 2024 | msn.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comDeutsche Bank Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)August 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Maravai Lifesciences Amid Strong Growth Prospects and Operational InvestmentsAugust 8, 2024 | seekingalpha.comMaravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | finance.yahoo.comMaravai LifeSciences Reports Second Quarter 2024 Financial ResultsSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/16/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees580Year FoundedN/APrice Target and Rating Average Stock Price Target$10.78 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+28.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-47.41% Pretax Margin214.04% Return on Equity-4.78% Return on Assets-2.33% Debt Debt-to-Equity Ratio0.71 Current Ratio10.00 Quick Ratio9.28 Sales & Book Value Annual Sales$278.59 million Price / Sales7.59 Cash Flow$0.09 per share Price / Cash Flow93.03 Book Value$3.14 per share Price / Book2.67Miscellaneous Outstanding Shares251,925,000Free Float250,338,000Market Cap$2.11 billion OptionableOptionable Beta0.01 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 65)Co-Founder & Executive Chairman Comp: $617.67kMr. William E. Martin III (Age 49)CEO & Director Comp: $987.86kMr. Kevin M. Herde (Age 52)Executive VP & CFO Comp: $548.62kDr. Peter Michael Leddy Ph.D. (Age 61)Executive VP & Chief Administrative Officer Comp: $583.39kMs. Christine Dolan (Age 56)Executive VP & GM of Cygnus Technologies Comp: $536.63kMr. Andrew Burch (Age 55)President of Nucleic Acid Production Comp: $425.15kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 43)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Rebecca BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANAscendis Pharma A/SNASDAQ:ASNDJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 253,887 shares on 8/27/2024Ownership: 0.418%Systematic Financial Management LPSold 99,491 shares on 8/16/2024Ownership: 0.558%Algert Global LLCBought 150,878 shares on 8/16/2024Ownership: 0.060%The Manufacturers Life Insurance Company Bought 43,372 shares on 8/15/2024Ownership: 0.017%Point72 Asia Singapore Pte. Ltd.Bought 4,449 shares on 8/15/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $6.55 at the start of the year. Since then, MRVI stock has increased by 38.6% and is now trading at $9.08. View the best growth stocks for 2024 here. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. Maravai LifeSciences's revenue for the quarter was up 6.5% on a year-over-year basis. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' top institutional shareholders include Gtcr LLC (8.00%), Millennium Management LLC (2.37%), Mackenzie Financial Corp (2.33%) and Massachusetts Financial Services Co. MA (1.81%). View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.